Viemed Healthcare, Inc. (VMD) 10-Year Financial Performance & Capital Metrics

VMD • • Industrial / General

HealthcareMedical DevicesRespiratory & Pulmonary DevicesSleep & Respiratory Therapy

AboutViemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.Show more

Revenue $224M +22.5%
EBITDA $43M +19.6%
Net Income $11M +10.0%
EPS (Diluted) 0.28 +12.0%
Gross Margin 59.4% -3.6%
EBITDA Margin 19.29% -2.4%
Operating Margin 7.98% +1.9%
Net Margin 5.02% -10.3%
ROE 9.11% -6.1%
ROIC 11.47% +2.6%
Debt/Equity 0.05 -43.2%
Interest Coverage 23.07 -31.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 22.8%
✓Efficient asset utilization: 1.3x turnover

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y25.42%

5Y22.82%

3Y24.2%

TTM18.9%

Profit (Net Income) CAGR

10Y1.77%

5Y5.73%

3Y7.27%

TTM30.55%

EPS CAGR

10Y-15.89%

5Y4.94%

3Y8.37%

TTM25.79%

ROCE

10Y Avg29.45%

5Y Avg16.75%

3Y Avg11.64%

Latest13.64%

Peer Comparison

Sleep & Respiratory Therapy

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
VMDViemed Healthcare, Inc.	286.66M	7.54	26.93	22.54%	5.34%	10.05%	0.46%	0.05
VVOSVivos Therapeutics, Inc.	20.2M	2.14	-0.96	8.91%	-98.77%	-6.76%		0.19

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	34.6M	31.36M	46.93M	65.27M	80.26M	131.31M	117.06M	138.83M	183.01M	224.26M
Revenue Growth %	0.49%	-0.09%	0.5%	0.39%	0.23%	0.64%	-0.11%	0.19%	0.32%	0.23%
Cost of Goods Sold+	7.82M	12.5M	12.31M	16.69M	24.25M	51.2M	43.65M	54.15M	70.22M	91.05M
COGS % of Revenue	0.23%	0.4%	0.26%	0.26%	0.3%	0.39%	0.37%	0.39%	0.38%	0.41%
Gross Profit+	26.78M	18.86M	34.62M	48.58M	56.01M	80.11M	73.41M	84.68M	112.78M	133.2M
Gross Margin %	0.77%	0.6%	0.74%	0.74%	0.7%	0.61%	0.63%	0.61%	0.62%	0.59%
Gross Profit Growth %	0.38%	-0.3%	0.84%	0.4%	0.15%	0.43%	-0.08%	0.15%	0.33%	0.18%
Operating Expenses+	16.74M	14.1M	20.65M	31.54M	47.15M	53.33M	61.83M	76.43M	98.45M	115.3M
OpEx % of Revenue	0.48%	0.45%	0.44%	0.48%	0.59%	0.41%	0.53%	0.55%	0.54%	0.51%
Selling, General & Admin	16.74M	13.77M	20.25M	30.95M	45.27M	57.71M	60.04M	73.36M	93.73M	112.48M
SG&A % of Revenue	0.48%	0.44%	0.43%	0.47%	0.56%	0.44%	0.51%	0.53%	0.51%	0.5%
Research & Development	0	0	0	0	848K	1.08M	2.11M	2.7M	2.78M	3.07M
R&D % of Revenue	-	-	-	-	0.01%	0.01%	0.02%	0.02%	0.02%	0.01%
Other Operating Expenses	0	332K	402K	-71K	1.03M	-5.46M	-323K	369K	1.94M	-249K
Operating Income+	10.04M	383K	8.82M	17.05M	8.86M	26.78M	11.58M	8.25M	14.33M	17.9M
Operating Margin %	0.29%	0.01%	0.19%	0.26%	0.11%	0.2%	0.1%	0.06%	0.08%	0.08%
Operating Income Growth %	0.06%	-0.96%	22.04%	0.93%	-0.48%	2.02%	-0.57%	-0.29%	0.74%	0.25%
EBITDA+	10.99M	1.81M	11.37M	20.83M	15.26M	36.36M	22.89M	23.88M	36.19M	43.27M
EBITDA Margin %	0.32%	0.06%	0.24%	0.32%	0.19%	0.28%	0.2%	0.17%	0.2%	0.19%
EBITDA Growth %	0.11%	-0.84%	5.29%	0.83%	-0.27%	1.38%	-0.37%	0.04%	0.52%	0.2%
D&A (Non-Cash Add-back)	955.09K	1.42M	2.54M	3.78M	6.4M	9.58M	11.31M	15.63M	21.86M	25.37M
EBIT	10.9M	383K	8.82M	10.11M	9.11M	26.87M	12.82M	9.19M	14.81M	16.95M
Net Interest Income+	0	-323K	-272K	-181K	-314K	-509K	-318K	-197K	-424K	-776K
Interest Income	87K	0	0	0	0	0	0	0	0	0
Interest Expense	0	323K	272K	181K	314K	509K	318K	197K	424K	776K
Other Income/Expense	-87K	-274K	-633K	-386K	-61K	-418K	923K	738K	61K	-1.73M
Pretax Income+	9.96M	109K	8.19M	10.34M	8.8M	26.36M	12.5M	8.99M	14.39M	16.17M
Pretax Margin %	0.29%	0%	0.17%	0.16%	0.11%	0.2%	0.11%	0.06%	0.08%	0.07%
Income Tax+	1.03M	-1.12M	15K	162K	271K	-5.17M	3.38M	2.77M	4.15M	4.76M
Effective Tax Rate %	0.9%	11.27%	1%	0.98%	0.97%	1.2%	0.73%	0.69%	0.71%	0.7%
Net Income+	8.93M	1.23M	8.18M	10.18M	8.53M	31.53M	9.13M	6.22M	10.24M	11.27M
Net Margin %	0.26%	0.04%	0.17%	0.16%	0.11%	0.24%	0.08%	0.04%	0.06%	0.05%
Net Income Growth %	-0.06%	-0.86%	5.66%	0.24%	-0.16%	2.7%	-0.71%	-0.32%	0.65%	0.1%
Net Income (Continuing)	9.69M	1.23M	8.18M	9.51M	8.53M	31.53M	9.13M	6.22M	10.24M	11.41M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	1.91M
EPS (Diluted)+	1.49	0.03	0.22	0.26	0.22	0.82	0.22	0.15	0.25	0.28
EPS Growth %	-0.06%	-0.98%	5.79%	0.18%	-0.15%	2.73%	-0.73%	-0.32%	0.67%	0.12%
EPS (Basic)	1.49	0.03	0.22	0.27	0.23	0.86	0.23	0.15	0.27	0.29
Diluted Shares Outstanding	6M	37.91M	37.97M	39.68M	39.75M	40.53M	40.68M	39.81M	40.38M	40.8M
Basic Shares Outstanding	6M	37.91M	37.91M	37.89M	37.72M	38.74M	39.49M	38.66M	38.35M	38.76M
Dividend Payout Ratio	0.73%	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.15M	11.2M	17M	22.96M	27.81M	47.17M	47.31M	39.74M	38.37M	52.88M
Cash & Short-Term Investments	3.15M	4.34M	5.1M	10.41M	13.36M	30.98M	28.41M	16.91M	12.84M	17.54M
Cash Only	3.15M	4.34M	5.1M	10.41M	13.36M	30.98M	28.41M	16.91M	12.84M	17.54M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	8.05M	4.79M	9.78M	8.84M	11.53M	12.37M	14.72M	15.4M	18.45M	24.91M
Days Sales Outstanding	84.87	55.79	76.08	49.43	52.46	34.39	45.88	40.5	36.8	40.55
Inventory	1.53M	1.64M	1.63M	2.89M	1.36M	2.31M	2.46M	3.57M	4.63M	4.32M
Days Inventory Outstanding	71.27	47.84	48.41	63.14	20.47	16.47	20.54	24.09	24.05	17.32
Other Current Assets	0	0	0	0	0	0	0	3.85M	2.45M	6.11M
Total Non-Current Assets+	9.26M	13.48M	20.69M	30.56M	54.78M	65.39M	70.65M	77.3M	116.53M	124.19M
Property, Plant & Equipment	9.26M	13.48M	20.69M	30.56M	54.77M	55.06M	62.85M	68.44M	76.85M	79.16M
Fixed Asset Turnover	3.74x	2.33x	2.27x	2.14x	1.47x	2.39x	1.86x	2.03x	2.38x	2.83x
Goodwill	0	0	0	0	0	0	0	0	29.77M	32.99M
Intangible Assets	0	0	0	0	0	0	0	0	567K	848K
Long-Term Investments	0	0	0	0	13K	733K	2.16M	4.16M	3.9M	2.79M
Other Non-Current Assets	0	0	0	0	0	863K	862K	1.59M	887K	0
Total Assets+	22.41M	24.68M	37.69M	53.52M	82.6M	112.56M	117.96M	117.04M	154.9M	177.07M
Asset Turnover	1.54x	1.27x	1.25x	1.22x	0.97x	1.17x	0.99x	1.19x	1.18x	1.27x
Asset Growth %	1.21%	0.1%	0.53%	0.42%	0.54%	0.36%	0.05%	-0.01%	0.32%	0.14%
Total Current Liabilities+	8.36M	9.17M	13.15M	16.98M	25.91M	23.02M	17.81M	18.86M	32.12M	37.33M
Accounts Payable	881K	1.88M	3.39M	5.88M	5.72M	3.35M	5.25M	4.9M	7.41M	5.32M
Days Payables Outstanding	41.12	55	100.37	128.69	86.14	23.87	43.9	33.05	38.51	21.33
Short-Term Debt	1.44M	458K	0	0	1.75M	1.84M	1.48M	0	1.07M	409K
Deferred Revenue (Current)	1000K	0	1000K	152K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	0	300K	-2.11M	3.13M	4.49M	2.34M	3.19M	6.52M	0
Current Ratio	1.57x	1.22x	1.29x	1.35x	1.07x	2.05x	2.66x	2.11x	1.19x	1.42x
Quick Ratio	1.39x	1.04x	1.17x	1.18x	1.02x	1.95x	2.52x	1.92x	1.05x	1.30x
Cash Conversion Cycle	115.03	48.64	24.11	-16.12	-13.21	26.99	22.53	31.54	22.34	36.53
Total Non-Current Liabilities+	2.4M	2.63M	798K	1.51M	12.98M	7.85M	5.33M	1.09M	8.88M	6.44M
Long-Term Debt	462K	0	0	0	7.63M	5.8M	4.31M	0	6M	3.59M
Capital Lease Obligations	1.94M	2.63M	798K	394K	3.04M	762K	268K	199K	2.32M	2.01M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	1.12M	2.32M	1.29M	757K	889K	558K	846K
Total Liabilities	10.76M	11.8M	13.95M	18.49M	38.9M	30.87M	23.14M	19.95M	41M	43.77M
Total Debt+	6.12M	6.49M	5.18M	3.42M	19.51M	11.13M	6.52M	694K	10.32M	6.87M
Net Debt	2.97M	2.15M	81K	-6.99M	6.16M	-19.85M	-21.89M	-16.22M	-2.52M	-10.67M
Debt / Equity	0.53x	0.50x	0.22x	0.10x	0.45x	0.14x	0.07x	0.01x	0.09x	0.05x
Debt / EBITDA	0.56x	3.59x	0.46x	0.16x	1.28x	0.31x	0.28x	0.03x	0.29x	0.16x
Net Debt / EBITDA	0.27x	1.19x	0.01x	-0.34x	0.40x	-0.55x	-0.96x	-0.68x	-0.07x	-0.25x
Interest Coverage	-	1.19x	32.44x	94.17x	28.21x	52.61x	36.42x	41.89x	33.80x	23.07x
Total Equity+	11.65M	12.88M	23.74M	35.03M	43.7M	81.69M	94.82M	97.09M	113.89M	133.3M
Equity Growth %	0.38%	0.11%	0.84%	0.48%	0.25%	0.87%	0.16%	0.02%	0.17%	0.17%
Book Value per Share	1.94	0.34	0.63	0.88	1.10	2.02	2.33	2.44	2.82	3.27
Total Shareholders' Equity	11.65M	12.88M	23.74M	35.03M	43.7M	81.69M	94.82M	97.09M	113.89M	131.39M
Common Stock	67K	67K	67K	71K	3.37M	9.18M	14.01M	15.12M	18.7M	23.36M
Retained Earnings	11.59M	12.81M	20.99M	29.57M	34.11M	65.64M	73.33M	69.85M	79.5M	89.69M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-5.73M	-8.82M	-157K	-451K	-278K	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	1.91M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	9.38M	6.41M	12.02M	22.37M	19.09M	35.11M	22.49M	27.75M	45.21M	39.09M
Operating CF Margin %	0.27%	0.2%	0.26%	0.34%	0.24%	0.27%	0.19%	0.2%	0.25%	0.17%
Operating CF Growth %	0.24%	-0.32%	0.87%	0.86%	-0.15%	0.84%	-0.36%	0.23%	0.63%	-0.14%
Net Income	8.93M	1.23M	8.18M	10.18M	8.53M	31.53M	9.13M	6.22M	10.24M	11.41M
Depreciation & Amortization	955.09K	1.42M	2.54M	3.78M	6.4M	9.58M	11.31M	15.63M	21.86M	25.37M
Stock-Based Compensation	0	0	828K	2.7M	3.89M	4.88M	5.15M	5.2M	5.85M	6.29M
Deferred Taxes	0	0	0	0	0	-8.73M	3.88M	1.75M	-1.44M	-3.84M
Other Non-Cash Items	5.82M	4.33M	5.34M	6.45M	9.81M	8.05M	6.58M	9.08M	921K	-488K
Working Capital Changes	-1.65M	-564K	-4.87M	-748K	-9.53M	-10.2M	-13.56M	-10.13M	7.78M	355K
Change in Receivables	-4.07M	-1.12M	-10.13M	-5.25M	-12.51M	-9.96M	-7.34M	-12.57M	-1.08M	-6.07M
Change in Inventory	-683.39K	-111K	5K	-1.25M	-306K	-2.3M	-212K	301K	-480.65K	574K
Change in Payables	1.99M	1.44M	900K	2.5M	783K	213K	133K	-318K	-874.75K	359K
Cash from Investing+	-132.63K	-936K	-3.57M	-5.3M	-12.81M	-8.41M	-19.75M	-23.98M	-52.11M	-30.7M
Capital Expenditures	-132.63K	-1.67M	-4M	-6.11M	-13.38M	-13.04M	-19.74M	-22.9M	-26.09M	-37.77M
CapEx % of Revenue	0%	0.05%	0.09%	0.09%	0.17%	0.1%	0.17%	0.16%	0.14%	0.17%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	738K	430K	813K	-13.34K	5.26M	596K	1.06M	2.57M	9.32M
Cash from Financing+	-7.86M	-4.29M	-7.69M	-11.75M	-3.33M	-9.07M	-5.32M	-15.27M	2.83M	-3.69M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-6.47M	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	4K	396K	1.88M	112K	283K	1.3M	789K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	9.25M	4.74M	8.02M	16.25M	5.7M	22.07M	2.75M	4.85M	19.12M	1.32M
FCF Margin %	0.27%	0.15%	0.17%	0.25%	0.07%	0.17%	0.02%	0.03%	0.1%	0.01%
FCF Growth %	0.37%	-0.49%	0.69%	1.03%	-0.65%	2.87%	-0.88%	0.76%	2.94%	-0.93%
FCF per Share	1.54	0.13	0.21	0.41	0.14	0.54	0.07	0.12	0.47	0.03
FCF Conversion (FCF/Net Income)	1.05x	5.22x	1.47x	2.20x	2.24x	1.11x	2.46x	4.46x	4.41x	3.47x
Interest Paid	0	0	0	193K	333K	559K	351K	0	851K	950K
Taxes Paid	0	0	0	151K	338K	3.31M	1.77M	0	3.57M	6.83M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	88.9%	10.01%	44.65%	34.63%	21.66%	50.29%	10.34%	6.48%	9.71%	9.11%
Return on Invested Capital (ROIC)	70.22%	1.94%	34.06%	49.29%	17.05%	35.96%	12.89%	8.05%	11.18%	11.47%
Gross Margin	77.4%	60.14%	73.76%	74.43%	69.78%	61.01%	62.71%	60.99%	61.63%	59.4%
Net Margin	25.8%	3.92%	17.42%	15.59%	10.62%	24.01%	7.8%	4.48%	5.6%	5.02%
Debt / Equity	0.53x	0.50x	0.22x	0.10x	0.45x	0.14x	0.07x	0.01x	0.09x	0.05x
Interest Coverage	-	1.19x	32.44x	94.17x	28.21x	52.61x	36.42x	41.89x	33.80x	23.07x
FCF Conversion	1.05x	5.22x	1.47x	2.20x	2.24x	1.11x	2.46x	4.46x	4.41x	3.47x
Revenue Growth	48.57%	-9.38%	49.66%	39.09%	22.96%	63.61%	-10.85%	18.6%	31.82%	22.54%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Equipment Sales	4.39M	7.36M	8.77M	13.93M	25.77M	30.9M
Equipment Sales Growth	-	67.39%	19.14%	58.89%	85.04%	19.89%
Service	1.42M	1.4M	2.05M	8.47M	10.66M	20.13M
Service Growth	-	-1.13%	46.32%	313.83%	25.90%	88.78%
COVID-19 Response Sales	-	34.38M	8.56M	2.28M	-	-
COVID-19 Response Sales Growth	-	-	-75.11%	-73.38%	-	-

Frequently Asked Questions

Valuation & Price

Viemed Healthcare, Inc. (VMD) has a price-to-earnings (P/E) ratio of 26.9x. This suggests investors expect higher future growth.

Growth & Financials

Viemed Healthcare, Inc. (VMD) reported $254.8M in revenue for fiscal year 2024. This represents a 994% increase from $23.3M in 2014.

Viemed Healthcare, Inc. (VMD) grew revenue by 22.5% over the past year. This is strong growth.

Yes, Viemed Healthcare, Inc. (VMD) is profitable, generating $13.6M in net income for fiscal year 2024 (5.0% net margin).

Dividend & Returns

Viemed Healthcare, Inc. (VMD) has a return on equity (ROE) of 9.1%. This is below average, suggesting room for improvement.

Viemed Healthcare, Inc. (VMD) generated $5.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...